Proactive Investors - Run By Investors For Investors

Imugene targets cash injection for immuno-oncology clinical testing

The halt will remain in place until Thursday 23rd November 2017.
Imugene targets cash injection for immuno-oncology clinical testing
The company's shares are in pre-open

Imugene Ltd (ASX:IMU) has commenced clinical testing a therapeutic anti-cancer vaccine called HER-Vaxx (IMU131), in HER2+ gastric cancer patients.

HER-Vaxx is a next generation HER2 cancer therapy using B cell peptides, which harness the body’s ability to develop antibodies against the disease.

HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two leading antibody drugs marketed by Roche, with annual sales of US$8.2 billion.

To progress the next steps, Imugene is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The halt will remain in place until the opening of trade on Thursday 23rd November 2017, or earlier if an announcement is made to the market.

View full IMU profile View Profile

Imugene Ltd Timeline

Newswire
October 19 2016

Related Articles

1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
blood
December 04 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use